ALLMedicine™ Anaplastic Oligoastrocytoma Center

Sep 28th, 2021 - Background: Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered a...

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Jul 16th, 2020 - Practice Essentials Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia. [1, ...

Jul 16th, 2020 - Oligodendroglioma is a well-differentiated, diffusely infiltrating tumor of adults that is typically located in the cerebral hemispheres and is predominantly composed of cells that morphologically resemble oligodendroglia.[1, 2] The hallmark molec...

Oct 15th, 2019 - Grading of Brain Tumors The widely used tumor-node-metastasis (TNM) classification system was found to be inappropriate for brain tumors, as tumor size is less relevant than tumor histology and location, the brain has no lymphatics, and most of th...

Oct 24th, 2017 - The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnos...

Sep 28th, 2021 - Background: Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3). It is orally administered a...

Jan 17th, 2019 - OBJECTIVES: To evaluate the diagnostic and prognostic relevance of various molecular, cytogenetic, and other tumor markers in high-grade glioma in paraffin-embedded tissue collected from patients enrolled in the Mayo Clinic or North Central Cancer...

Mar 21st, 2017 - The multimodality approach for management of primary and secondary brain tumors includes surgery, radiotherapy and chemotherapy. Determination of an objective response to treatment relies on imaging findings (e.g. CT, MRI, PET).During the course o...

Mar 14th, 2017 - Phase I Primary Objective • To determine the maximum tolerated dose (MTD) of LBH589 in combination with bevacizumab given at 10 mg/kg every 2 weeks in patients with recurrent glioblastoma (GBM), gliosarcoma, anaplastic astrocytoma, anaplastic olig...

Apr 26th, 2016 - Patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma will be enrolled. Enrolled patients will begin on temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). Pat...

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Dec 5th, 2020 - Victor A. Levin, MD Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA). A rare form of brain tu...